Desoxyepothilone B clinical trials
Also written Utidelone and KOS-862.
How each study uses desoxyepothilone B is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the desoxyepothilone B studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2023 (9)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 3 |
| 2004 | 2 |
| 2014 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 9 |
| 2024 | 6 |
| 2025 | 5 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 19 · Other 20
Beijing Biostar Pharmaceuticals Co., Ltd. (13) · Henan Cancer Hospital (4) · Bristol-Myers Squibb (3) · Fudan University (3) · Memorial Sloan Kettering Cancer Center (2) · Biostar Pharma, Inc. (2) · Hunan Cancer Hospital (2) · Min Yan, MD (1)
Often tested with
Tested in the same studies.
Capecitabine (8) · Bevacizumab (5) · Toripalimab (1) · HMPL-013 (1) · Cisplatin (1) · Oxaliplatin (1) · Tislelizumab (1) · Anlotinib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 7
Studies that test desoxyepothilone B.
- Dec 2026Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain MetastasesPhase 2 · Beijing Biostar Pharmaceuticals Co., Ltd.
- Dec 2026Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast CancerPhase 2 · Henan Cancer Hospital
- Dec 2026Utidelone Capsule Monotherapy for Patients with Advanced Solid TumorsPhase 2 · Beijing Biostar Pharmaceuticals Co., Ltd.
- Jan 2027A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain MetastasesPhase 2 · Biostar Pharma, Inc.
- Mar 2027Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerPhase 2 · Beijing Biostar Pharmaceuticals Co., Ltd.
- Mar 2027Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)Phase 2 · RenJi Hospital
- Jun 2027Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian CancerPhase 2 · Fudan University
Studies
Open first, then newest update. How each study uses desoxyepothilone B is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 39
- A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBCRecruitingPhase 2Henan Cancer HospitalNCT06598046Written as Utidelone and capecitabine
- A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain MetastasesRecruitingPhase 2Biostar Pharma, Inc.NCT06764940Written as Utidelone
- Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast CancerNot yet recruitingPhase 3Beijing Biostar Pharmaceuticals Co., Ltd.NCT07684456Written as Utidelone Capsule
- Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT05398861Written as utidelone injection
- A Phase II Study of Utidelone With Toripalimab in Advanced Cervical CancerNot yet recruitingPhase 2Zhongnan HospitalNCT07363330Written as Utidelone plus Toripalimab
- Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2/3Beijing Biostar Pharmaceuticals Co., Ltd.NCT06841679Written as Utidelone Capsule
- Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerNot yet recruitingPhase 2Beijing Biostar Pharmaceuticals Co., Ltd.NCT07044349Written as Utidelone capsule 75mg/m2/d QD
- Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC PatientsNot yet recruitingPhase 3Fudan UniversityNCT07021261Written as Utidelone plus capecitabine
- Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingPhase 2Fudan UniversityNCT06973421Written as Utidelone Capsules
- UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain MetastasesRecruitingPhase 1/2Hunan Cancer HospitalNCT05535413Written as UTD1 combined with capecitabine
- Utidelone Capsule Monotherapy for Patients with Advanced Solid TumorsNot yet recruitingPhase 2Beijing Biostar Pharmaceuticals Co., Ltd.NCT06730581Written as Utidelone Capsule 60mg/m2/d
- Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain MetastasesNot yet recruitingPhase 2Beijing Biostar Pharmaceuticals Co., Ltd.NCT06683703Written as Utidelone combined with Bevacizumab
- Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)Not yet recruitingPhase 2RenJi HospitalNCT06510465Written as utidelone
- Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant TherapyRecruitingPhase 2Hunan Cancer HospitalNCT06385990Written as UTD1
- The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) :Single-arm, Prospective, Open Clinical StudyRecruitingPhase 2Huihua XiongNCT06125080Written as Utidelone
- Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast CancerRecruitingPhase 3Beijing Biostar Pharmaceuticals Co., Ltd.NCT05673629Written as Utidelone Injection in combination with AC
- Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingPhase 3Beijing Biostar Pharmaceuticals Co., Ltd.NCT05673590Written as Utidelone Injection
- Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Sun Yat-sen UniversityNCT05430399Written as utidelone
- Utidelone Treated for the Recurrent or Metastatic Urothelial CarcinomaRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05895864Written as utidelone injection
- Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal CancerRecruitingPhase 2Peking UniversityNCT05866510Written as Utidelone and anlotinib
See all 39 studies that test desoxyepothilone B →
Given beside what is tested · 3 — desoxyepothilone B is usual care or a partner of the new treatment
- Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingPhase 2Fudan UniversityNCT06355037Written as Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
- Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast CancerNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05983094Written as Utidelone
- Inosine Reverse Chemo Resistance in Triple Negative Breast CancerCompletedPhase 2Fudan UniversityNCT06355024Written as Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
As the comparator · 1 — what is tested is compared with desoxyepothilone B
Codes
What other systems call desoxyepothilone B · ClinicalTrials.gg INT004091
- MeSH (NLM) C114026desoxyepothilone BOne source NLM
- UNII (FDA) T0358E0YUFUTIDELONEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C114026 | desoxyepothilone B | One source NLM |
| UNII (FDA) | T0358E0YUF | UTIDELONE | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.